176 related articles for article (PubMed ID: 20729007)
1. Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.
Karlsson P; Cole BF; Colleoni M; Roncadin M; Chua BH; Murray E; Price KN; Castiglione-Gertsch M; Goldhirsch A; Gruber G;
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):398-402. PubMed ID: 20729007
[TBL] [Abstract][Full Text] [Related]
2. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group.
Benchalal M; Le Prisé E; de Lafontan B; Berton-Rigaud D; Belkacemi Y; Romestaing P; Peignaux K; Courdi A; Monnier A; Montcuquet P; Goudier MJ; Marchal C; Chollet P; Abadie-Lacourtoisie S; Datchary J; Veyret C; Kerbrat P
Cancer; 2005 Jul; 104(2):240-50. PubMed ID: 15948160
[TBL] [Abstract][Full Text] [Related]
3. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
van Hezewijk M; Bastiaannet E; Putter H; Scholten AN; Liefers GJ; Rea D; Hasenburg A; Paridaens R; Hozumi Y; Markopoulos C; Seynaeve C; Jones SE; Marijnen CA; van de Velde CJ
Radiother Oncol; 2013 Aug; 108(2):190-6. PubMed ID: 24044798
[TBL] [Abstract][Full Text] [Related]
4. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Fisher B; Jeong JH; Anderson S; Wolmark N
J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
[TBL] [Abstract][Full Text] [Related]
5. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
Shurell E; Olcese C; Patil S; McCormick B; Van Zee KJ; Pilewskie ML
Cancer; 2018 Jan; 124(1):46-54. PubMed ID: 28960259
[TBL] [Abstract][Full Text] [Related]
6. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Han W; Han MR; Kang JJ; Bae JY; Lee JH; Bae YJ; Lee JE; Shin HJ; Hwang KT; Hwang SE; Kim SW; Noh DY
BMC Cancer; 2006 Apr; 6():92. PubMed ID: 16608533
[TBL] [Abstract][Full Text] [Related]
7. Benefit of radiation boost after whole-breast radiotherapy.
Livi L; Borghesi S; Saieva C; Fambrini M; Iannalfi A; Greto D; Paiar F; Scoccianti S; Simontacchi G; Bianchi S; Cataliotti L; Biti G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1029-34. PubMed ID: 19395193
[TBL] [Abstract][Full Text] [Related]
8. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
9. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
10. No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.
Killander F; Karlsson P; Anderson H; Mattsson J; Holmberg E; Lundstedt D; Holmberg L; Malmström P
Eur J Cancer; 2016 Nov; 67():57-65. PubMed ID: 27614164
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
[TBL] [Abstract][Full Text] [Related]
12. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
13. Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe.
Wickberg Å; Liljegren G; Killander F; Lindman H; Bjöhle J; Carlberg M; Blomqvist C; Ahlgren J; Villman K
Eur J Surg Oncol; 2018 Jul; 44(7):951-956. PubMed ID: 29709338
[TBL] [Abstract][Full Text] [Related]
14. The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival.
van Maaren MC; Bretveld RW; Jobsen JJ; Veenstra RK; Groothuis-Oudshoorn CG; Struikmans H; Maduro JH; Strobbe LJ; Poortmans PM; Siesling S
Br J Cancer; 2017 Jul; 117(2):179-188. PubMed ID: 28588320
[TBL] [Abstract][Full Text] [Related]
15. Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment.
Livi L; Paiar F; Saieva C; Scoccianti S; Dicosmo D; Borghesi S; Agresti B; Nosi F; Orzalesi L; Santini R; Barca R; Biti GP
Radiother Oncol; 2007 Mar; 82(3):287-93. PubMed ID: 17188382
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
Borgquist S; Giobbie-Hurder A; Ahern TP; Garber JE; Colleoni M; Láng I; Debled M; Ejlertsen B; von Moos R; Smith I; Coates AS; Goldhirsch A; Rabaglio M; Price KN; Gelber RD; Regan MM; Thürlimann B
J Clin Oncol; 2017 Apr; 35(11):1179-1188. PubMed ID: 28380313
[TBL] [Abstract][Full Text] [Related]
17. Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
Yan Y; Zhang L; Tan L; Ma X; Zhang Y; Shao S; Liu J; Xue C; Li Z; Zhang X; Drokow EK; Shi X; Ren J
Pathol Oncol Res; 2020 Jan; 26(1):521-531. PubMed ID: 30499075
[TBL] [Abstract][Full Text] [Related]
18. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.
Jabro G; Wazer DE; Ruthazer R; Lum R; Sklar N; Goldman D; Enegess D; Erban J
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):273-80. PubMed ID: 10760419
[TBL] [Abstract][Full Text] [Related]
19. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
Han S; Kim J; Sohn S; Kwak GH; Kim JY; Park K
J Surg Oncol; 2007 Jan; 95(1):45-50. PubMed ID: 17192866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
